Faron Pharmaceuticals Oy logo

FARN - Faron Pharmaceuticals Oy Share Price

284p 4.0  1.4%

Last Trade - 11/12/19

Sector
Healthcare
Size
Small Cap
Market Cap £110.2m
Enterprise Value £109.7m
Revenue £-0.843k
Position in Universe 951st / 1843
Bullish
Bearish
Unlock FARN Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

FARN Revenue Unlock FARN Revenue

Net Income

FARN Net Income Unlock FARN Revenue

Normalised EPS

FARN Normalised EPS Unlock FARN Revenue

PE Ratio Range

FARN PE Ratio Range Unlock FARN Revenue

Dividend Yield Range

FARN Dividend Yield Range Unlock FARN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2019
31st Dec 2020
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
FARN EPS Forecasts Unlock FARN Revenue
Profile Summary

Faron Pharmaceuticals Oy is a Finland-based clinical stage biopharmaceutical company. The Company’s pipeline is based on endothelial receptors involved in regulation of immune responses and focuses on acute organ traumas, vascular damage and cancer immunotherapy. The Company has two technological platforms: Traumakine and Clevegen. Traumakine aims to prevent vascular leakage and organ failure under ischemic condition. It is undergoing Phase III clinical trials for the treatment of Acute Respiratory Distress Syndrome (ARDS) and European Phase II trial for the prevention of multi-organ failure after emergency aortic surgery for a Rupture of Abdominal Aorta Aneurysm (RAAA). Clevegen is a ground breaking early clinical anti-Clever-1 antibody able to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. It may be used alone or in combination with other immune checkpoint molecules.

Directors
Last Annual December 31st, 2018
Last Interim June 30th, 2019
Incorporated October 24, 2006
Public Since November 17, 2015
No. of Shareholders: n/a
No. of Employees: 25
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Aim All Share ,
Exchange London Stock Exchange (AIM)
Shares in Issue 39,355,247
Free Float (0.0%)
Eligible for
ISAs
SIPPs
Address Joukahaisenkatu 6, TURKU, 20520, Finland
Web https://www.faron.com/
Phone +358 2 4695151
Contact ()
Auditors PricewaterhouseCoopers Oy
FARN Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for FARN
Upcoming Events for FARN
Wednesday 27th May, 2020 Estimate
Faron Pharmaceuticals Oy Annual Shareholders Meeting
Similar to FARN
© Stockopedia 2019, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.